Navigation Links
China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008

NEW YORK, Nov. 15 /PRNewswire-FirstCall/ -- China Aoxing Pharmaceutical Company, Inc. (OTC Bulletin Board: CAXG), which has the largest manufacturing facility and product pipeline for highly regulated narcotic medicines and pain medication in China, today announced financial results for the first quarter of fiscal 2008 ended September 30, 2007.

China Aoxing Pharmaceutical Company reported revenues of $1,380,294 for the first quarter of fiscal 2008, a 33% sequential increase from the fourth quarter of fiscal 2007, reflecting sales of Naloxone Hydrochloride, an analgesic used to reverse the effects of narcotic drugs used during surgery, and Shuanghuanglian, a traditional Chinese medicine treatment for cough and cold. Gross profit during this period was $754,641, a gross profit margin of 55%.

Zhenjiang Yue, Chairman and Chief Executive Officer of China Aoxing Pharmaceutical stated, "We are pleased to report strong business progress and financial results for the first quarter of fiscal 2008. Driven by continued execution of our business strategy and solid growth in our core product portfolio, sales in the fourth quarter of fiscal 2007 reached to $1.38 million. We see the continuous growth trend of our first narcotic drug, Naloxone Hydrochloride, which was launched in February 2007. We continue receiving positive feedback on our pipeline development from the China State Food & Drug Administration (SFDA) and we are very optimistic about our Company's opportunity to bring to China established narcotics and pain medicines, which are industry standards in the United States and Europe. We move aggressively into the commercialization stage of our pipeline products, most of which are expected to be launched over the next twelve to eighteen months."

Total operating costs and expenses for the first quarter of fiscal 2008 were $1.77 million, which reflected approximately $815,103 of general and administrative expense attributable to the production, sales and marketing of products. In addition, the Company amortized $519,915 of non-cash deferred interest expense, and recognized interest expense of $259,303 as well as $57,262 of research and development costs. The Company reported a net loss of $1.02 million in the first quarter of fiscal 2008.

Balance Sheet

As of September 30, 2007, the Company had $1.03 million of cash. China Aoxing Pharmaceutical had a working capital deficit of approximately $9.7 million as of September 30, 2007. The Company had total borrowings of $15.2 million as of September 30, 2007.

Zhenjiang concluded, "Our goal is to be a leading, fully integrated narcotic drug and pain medicine company in China. For the remainder of the calendar year, we will be diligently continuing our sales efforts of approved products as well as completing and integrating our LRT acquisition. In addition, as a long term growth strategy, we are actively evaluating external opportunities including pharmaceutical and biotech products or businesses offering leading technology platform, competitive products, high technical and regulatory advantages."

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTC Bulletin Board: CAXG) is a pharmaceutical company in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain management products. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, the Company has the largest product pipeline and largest manufacturing facility (1.2 million sq. ft.) for highly regulated narcotic medicines, addressing a very under-served market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company has two drugs on the market and has received China SFDA licenses for seven more medications such as Oxycodone, Tilidine and Pholcodine. The Company is working closely with the Chinese government and SFDA to assure the availability of narcotic drugs and pain medicines throughout China.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. You are urged to read the Company's filings with the Securities and Exchange Commission, including, but not limited to, the risk factors contained therein. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.


Dr. Hui Shao

Senior Vice President

China Aoxing Pharmaceutical


China Aoxing Pharmaceutical Co., Inc. and Subsidiaries


SEPTEMBER 30, 2007



Cash $1,030,721

Accounts receivable 155,966

Inventories 321,732

Prepaid expenses and sundry current assets 200,973




TOTAL ASSETS $30,045,521


Short-term borrowings $266,042

Accounts payable 638,781

Loan payable - other 573,550

Due to stockholders 685,798

Accrued expenses and taxes payable 2,286,924

Current portion of long-term debt 6,983,473


LONG-TERM DEBT 4,389,699



Common stock, $0.001 par value,

100,000,000 shares authorized

41,595,507 shares issued and outstanding 40,595

Preferred stock, $0.001 par value,

300,000 shares authorized

277,018 shares issued and outstanding 277

Additional paid-in capital 19,470,686

Deferred stock compensation (255,277)

Accumulated deficit (7,807,723)

Other comprehensive income 425,696






2007 2006

SALES $1,380,294 $-

COST OF SALES 625,653 -

GROSS PROFIT 754,641 -


Research and development 57,262 10,067

General and administrative 815,103 201,386

Interest expense 259,303 329,031

Depreciation and amortization 118,812 -

Amortization of deferred interest 519,915 56,913

TOTAL COSTS AND EXPENSES 1,770,395 597,397

NET LOSS $(1,015,754) $(597,397)

Basic and diluted earnings per

common share $(0.03) $(0.01)

Weighted average number of shares

outstanding 40,453,009 40,050,000

SOURCE China Aoxing Pharmaceutical Company, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... the healthcare and technology sector at their fourth annual Conference where founders, investors, ... inspiring speakers and the ELEVATE pitch competition showcasing early stage digital health and ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading ... around the world, is giving back to cancer research with a month-long promotion supporting ... Now through October 31, shoppers can use promo code PinkRibbon to get 10 percent ...
(Date:10/5/2017)... , ... October 05, 2017 , ... ... develop new applications of its Nanobind DNA/RNA extraction technology . Nanobind is ... silica on the surface and that can be used for a wide variety ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):